As the CEO and Founder of Atheon Bio, Inc., a pioneering Korean startup in the development of cancer immunotherapies targeting the tumor microenvironment, Dr. Choe stands at the forefront of innovation in the biotechnology field. With over two decades of experience in the pharmaceutical and biotechnology industries, Dr. Choe’s comprehensive expertise spans business, technology, and law, underpinning her effective corporate leadership and broad cross-industry knowledge, grounded in a robust technical foundation. Her adeptness in steering R&D initiatives towards the commercialization of technology is particularly notable in the realm of immuno-oncology, including antibody, bispecific antibody, CAR-T and T cell therapies. Holding a bachelor’s degree in Chemistry from Seoul National University, Dr. Choe furthered her education with a Ph.D. in Biochemistry from the University Wisconsin-Madison, USA. She also holds a J.D. from the University of Minnesota Law School. Dr. Choe’s forward-thinking strategy for commercializing technology merges intellectual property, R&D, market analysis, business insights for new drugs, establishing biotechnology companies as frontrunners in the field of innovative drug development.